Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 2/20 | 0.32 |
| ▸ | CNR2 | P34972 | 2/20 | 0.32 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.31 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.31 |
| ▸ | NMT1 | P30419 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.31 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.30 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31268747 | 0.91 | CNR1 (0.36) | PIK3CDDGAT1CNR1CNR2ALK | |
| SCHEMBL31269465 | 0.91 | HSD17B13 (0.37) | PIK3CDGPR119DGAT1CNR1CNR2 | |
| SCHEMBL31269014 | 0.90 | PIK3CD (0.34) | PIK3CDDGAT1CNR1CNR2 | |
| SCHEMBL31269290 | 0.89 | PIK3CD (0.37) | PIK3CDDGAT1CNR1CNR2ROCK2 | |
| SCHEMBL31269283 | 0.89 | PIK3CD (0.38) | PIK3CDDGAT1CNR1CNR2TDP1 | |
| SCHEMBL31269337 | 0.88 | CNR1 (0.39) | PIK3CDGPR119DGAT1CNR1CNR2 | |
| SCHEMBL31268799 | 0.87 | DGAT1 (0.35) | PIK3CDDGAT1CNR1CNR2 | |
| SCHEMBL31268788 | 0.87 | PIK3CD (0.37) | PIK3CDDGAT1CNR1CNR2 | |
| SCHEMBL30983368 | 0.86 | PIK3CD (0.36) | PIK3CDDGAT1CNR1CNR2 | |
| SCHEMBL31268878 | 0.86 | PIK3CD (0.36) | PIK3CDDGAT1CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4689155-A1 | USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS | Astrazeneca AB (SE) | 2026-02-11 | — | — | EP | disclosed |
| WO-2024201368-A1 | USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS | ASTRAZENECA AB (SE) | 2024-10-03 | — | — | WO | disclosed |